ALS/MND researchers from around the world convened virtually from December 7-10. The aim is to share knowledge and learn about the most recent advances in the field at the 32nd International Symposium on ALS/MND. John, Anne, and Lisa also attended the conference.
The content of the conference was very diverse with presentations about cell biology, pathology and translational research. Of note, both oral and poster presentations have touched upon metabolism and changes in the microbiome in ALS, which are some of our key interests in ALS research.
Amyotrophic Lateral Sclerosis (ALS) is also referred to as motor neuron disease (MND) or Lou Gehrig’s Disease. ALS is a rapidly, invariably fatal neurodegenerative disease that affects people all over the world, with over 60.000 people living with ALS today. ALS was first diagnosed in 1874. Despite 140 years of research and development, the cause remains unknown, with no effective treatment, let alone a cure.
The MND Association helps to change the lives of people living with MND by improving access to care, research, and raising awareness. They fund and promote research that leads to new knowledge and treatments and helps us to find a cure. Next, they organise the International Symposium on ALS/MND.
About the symposium
The symposium is the world’s biggest medical and scientific conference dedicated to MND/ALS. It aims to bring together researchers, social care professionals, as well as people living with ALS/MND from all over the world to encourage strong collaboration. During the conference, they present and debate the latest news and key innovations.
The next edition will be held in San Diego, California, from December 7-9 2022.